Researchers at Korea's National Cancer Center have released new real-world data (RWD) supporting the use of Yuhan Corp's Leclaza (lazertinib) in the treatment of a subset of non-small cell lung cancer (NSCLC). The study, basefd on data from 103 patients who used Leclaza as a second-line treatment, showed that the drug improved median progression-free survival (mPFS) out to 13.9 months, an improvement on the 11.1 months mPFS demonstrated in a randomized clinical trial.
According to Jeong Min-jun, “In this RWD study, the treatment effect of Leclaza in patients with brain metastases was equally significant as in the LASER201 study. In 33 patients with brain metastases with analyzable intracranial lesions, the median intracranial progression-free survival (mIPFS) was 17.1 months, with an objective response rate of 57.6 percent.”
To read more, click here.
(Source: Korean Biomedical Review, May 22nd, 2023)